Tandem Diabetes Care (TNDM) Research & Development (2013 - 2026)

Tandem Diabetes Care's Research & Development history runs 14 years deep, the most recent figure standing at $46.0 million for Q1 2026.

• Quarterly Research & Development fell 8.32% year-over-year to $46.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.9 million (down 6.86% YoY) and the FY2025 annual result came in at $193.1 million, down 2.9% from the prior year.
• Research & Development was $46.0 million for Q1 2026 at Tandem Diabetes Care, roughly flat from $46.1 million in the prior quarter.
• Across five years, Research & Development topped out at $52.2 million in Q4 2024 and bottomed at $33.2 million in Q1 2022.
• A 5-year average of $43.9 million and a median of $46.0 million in 2026 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development jumped 84.62% — and 2025, when it slipped 11.75%.
• Tandem Diabetes Care's Research & Development stood at $35.6 million in 2022, then gained by 19.72% to $42.6 million in 2023, then increased by 22.52% to $52.2 million in 2024, then declined by 11.75% to $46.1 million in 2025, then declined by 0.07% to $46.0 million in 2026.
• Business Quant data shows TNDM's Research & Development at $46.0 million in Q1 2026, $46.1 million in Q4 2025, and $48.7 million in Q3 2025.